Merck Stock News

The FDA has halted all clinical trials testing the injectable form of Gilead''s lenacapavir, for fear that incompatibility between the drug and the vials it''s held in could cause contamination.

https://it.investing.com/news/stock-market-news/covid-francia-annulla-ordine-per-farmaco-antivirale-merck-2033355

France has canceled its order for Merck’s new Covid-19 antiviral treatment molnupiravir due to its weak performance in trials, and ordered Pfizer’s Paxlovid instead, Health Minister Olivier Veran said on Wednesday. Read Full Article at RT.com

The US Food and Drug Administration is set to authorize COVID-19 treatment pills from both Pfizer Inc and Merck as early as Wednesday, Bloomberg News reported on Tuesday, citing people familiar with the matter. The post US FDA set to authorise Pfizer, Merck COVID-19 pills this week: Bloomberg News appeared first on SABC News - Breaking news, special reports, world, business, sport coverage of all South African current events. Africa''s news leader. .

The FDA is set to authorize COVID-19 treatment pills from Pfizer Inc (NYSE: PFE ) and Merck & Co Inc (NYSE: MRK ) as early as Wednesday, Bloomberg reported , citing people familiar with the matter. The two drugs, especially Pfizer''s pill Paxlovid, are seen as promising new oral treatments that can be taken upon onset of symptoms at home to help prevent COVID-19 hospitalizations and deaths. Merck''s drug, molnupiravir, Full story available on Benzinga.com

The U.K. government will buy more COVID-19 antiviral pills from Pfizer Inc (NYSE: PFE ) and Merck & Co Inc (NYSE: MRK ) as it seeks to combat the surge in omicron infections. Britain has secured an additional 1.75 million courses of Merck’s drug, molnupiravir, and another 2.5 million courses of Pfizer’s paxlovid. Previously the U.K. had sourced 480,000 courses of molnupiravir and … Full story available on Benzinga.com

Included in the order are 2.5million more doses of Pfizer''s Paxlovid, which has been shown to slash the risk of vulnerable adults being hospitalised by up to 90%, and 1.75m courses of Lagevrio.

The UK health department has fast-tracked two new deals with Merck and Pfizer to secure an additional 4.25m courses of their anti-Covid pills as it lines The UK health department has fast-tracked two new deals with Merck and Pfizer to secure an additional 4.25m courses of their anti-Covid pills as it lines up defences for the NHS ahead of an expected winter wave of the new Omicron variant.

Here''s a roundup of top developments in the biotech space over the last 24 hours. Stocks In Focus Allakos''s Lirentelimab Flunks Late-Stage Studies In Patients With Inflammation In Digestive Tract Allakos, Inc. (NASDAQ: ALLK ) announced data from ENIGMA 2 Phase 3 study of lirentelimab in patients with biopsy confirmed eosinophilic gastritis and/or eosinophilic duodenitis and KRYPTOS Phase 2/3 study of lirentelimab in patients with biopsy-confirmed eosinophilic esophagitis. Both ENIGMA 2 and KRYPTOS studies met their histologic co-primary endpoints, but did not achieve statistical significance on the patient reported symptomatic co-primary endpoints. The stock was down 7.69% to $77.90 in premarket trading. FDA Imposes Clinical Hold On Injectable Form Of Gilead''s HIV Drug Candidate Due to Concerns Over Vial Quality Gilead Sciences, Inc. (NASDAQ: GILD ) announced that the U.S. Food and Drug Administration has placed a clinical hold on the use of injectable lenacapavir in borosilicate vials in all ongoing clinical studies for HIV treatment and HIV pre-exposure prophylaxis.

Miracle Mile Advisors LLC increased its position in Merck & Co., Inc. (NYSE:MRK) by 52.6% in the 3rd quarter, according to its most recent filing with the SEC. The fund owned 10,795 shares of the company’s stock after purchasing an additional 3,723 shares during the period. Miracle Mile Advisors LLC’s holdings in Merck & Co., […]

Israel Rolls Out Plan For 2nd Booster Shots, UK Sees Omicron Hospitalizations Rise To 14 As far as COVID news Wednesday morning, the flow has been particularly heavy out of the UK, where the government''s scientific advisors are reportedly ready to officially declare that those who become infected with the omicron strain are less likely to become severely ill, something that health experts in South Africa (where the variant was first identified) and around the world is likely true (though we only have a few weeks'' worth of data to go on right now). But despite this, the variant is still not mild enough to avoid causing large numbers of hospitalizations. The data is culled from the UK Health Security Agency''s upcoming report on the severity of the disease before Christmas, Politico reported. And speaking of hospitalizations, the number of patients hospitalized with COVID caused by the omicron variant has climbed to 129 as of Wednesday morning, according to data released by HMG. Leaving aside the issue of the new variant''s inherent infectiousness, governments around the world expect the coming winter wave to be milder than last year''s - at least in terms of the number of deaths and hospitalizations threatening to overwhelm the system - because many more (literally billions) have been vaccinated since this time last year.

KENILWORTH, N.J. & MIAMI--(BUSINESS WIRE)---- $MRK #MRK--Merck and Ridgeback Announce U.K. Government to Purchase Additional 1.75 Million Courses of Molnupiravir

Global Microbial Fermentation APIs Market 2021-2027, has been prepared based on an in-depth market analysis with inputs from industry experts. The report covers the market landscape and its growth prospects in the coming years. The report includes a discussion of

SYDNEY: Singapore suspended quarantine-free travel and Australia renewed its vaccination push on Wednesday as surging cases of the Omicron coronavirus variant just days before Christmas forced authorities to impose new curbs and expedite booster shots. Governments globally have tightened social mobility restrictions and made urgent pleas for citizens to vaccinate as Omicron emerges as the dominant strain of the virus, upending reopening plans that many hoped would herald the start of a post-pandemic era in 2022. In Asia-Pacific, Singapore will freeze all new ticket sales for flights and buses under its programme for quarantine-free travel into the city-state from Dec. 23 to Jan. 20, the government said on Wednesday, citing risk from the fast-spreading Omicron. "Our border measures will help to buy us time to study and understand the Omicron variant, and to strengthen our defences, including enhancing our healthcare capacity, and getting more people vaccinated and boosted," Singapore''s health ministry said in a statement.